Sage Therapeutics, Inc., (NASDAQ:SAGE) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Ashley Kaplowitz - Vice President of Investor Relations and Capital Markets Barry Greene - Chief Executive Officer Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Salveen Richter - Goldman Sachs Anupam Rama - JPMorgan Yasmeen Rahimi - Piper Sandler Paul Matteis ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact name of registrant as specifi ...

Exhibit 99. 1 Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress Achieved $7.4 million in ZURZUVAE™ (zuranolone) collaboration revenue during the second quarter of 2024 (50% of the net revenues recorded by Biogen), representing 19% growth from the first quarter More than 1,400 prescriptions shipped and delivered during the second quarter of 2024, nearly doubling from the first quarter Dalzanemdor (SAGE-718) topline data from the LIGHTWAVE (Alzheim ...

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 31. On the other hand, if they miss, the stock may move lower. Zacks Consensus Estimate Estimate Revisions Trend Earnings Whisper Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. How Have t ...

The company's first marketed drug, Zulresso (brexanolone), was approved by the FDA in 2019 as the first-ever FDA-approved treatment for adults with postpartum depression (PPD). SAGE markets Zurzuvae in partnership with drug giant Biogen (BIIB) . Sage and BIIB are focused on establishing Zurzuvae as a first-line therapy and the standard of care for women with PPD. Image Source: Zacks Investment Research Last month, the company reported that the phase II SURVEYOR study evaluating dalzanemdor as a potential tr ...

Sage Therapeutics (SAGE) announced that the phase II SURVEYOR study evaluating its lead neuropsychiatric candidate, dalzanemdor (SAGE-718), as a potential treatment for patients with cognition dysfunction caused by Huntington's disease (HD), met its primary endpoint. Shares of the company were however down 2.8% on Jun 11 following the announcement of the news. The SURVEYOR study compared dalzanemdor versus placebo in participants with HD for a 28-day treatment period. The three main objectives of the SURVEY ...

NEW YORK, May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Sage and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On April 17, 2024, Sage ...

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Conference Call April 25, 2024 8:00 AM ET Company Participants Ashley Kaplowitz - Vice President-Investor Relations & Capital Markets Barry Greene - Chief Executive Officer & Member-Board of Directors Chris Benecchi - Chief Business Officer Laura Gault - Chief Medical Officer Kimi Iguchi - Chief Financial Officer Mike Quirk - Chief Scientific Officer Conference Call Participants Anupam Rama - JPMorgan Ritu Baral - TD Cowen Laura Chico - Wedbush Securiti ...

First Quarter 2024 Financial Results April 25, 2024 Safe Harbor Statement • The slides presented todayand the accompanying oral presentations contain forward-looking statements, which may be identified by the use of words such as "may," "might," "will," "should," "can," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "opportunity","goal", "mission", "potential," "target", or "continue," and other similar expressions. • Forward-looking statements in this presentation inc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-36544 Sage Therapeutics, Inc. (Exact name of registrant as specified in its Charter) (State or other jurisdiction of incorpor ...